已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparing 3-year survival and readmissions between HeartMate 3 and heart transplant as primary treatment for advanced heart failure

医学 心力衰竭 心脏移植 心脏病学 内科学 心脏移植 重症监护医学
作者
Michael Kirschner,Veli K. Topkara,Jocelyn Sun,Paul Kurlansky,Yuji Kaku,Yoshifumi Naka,M. Yuzefpolskaya,P.C. Colombo,Gabriel Sayer,Nir Uriel,Koji Takeda
出处
期刊:The Journal of Thoracic and Cardiovascular Surgery [American Association for Thoracic Surgery]
被引量:4
标识
DOI:10.1016/j.jtcvs.2023.12.019
摘要

To compare 3-year survival and readmissions of patients who received the HeartMate 3 (HM3) left ventricular assist device (LVAD) or underwent orthotopic heart transplantation (OHT) as primary treatment for advanced heart failure.We retrospectively analyzed 381 adult patients who received an HM3 LVAD or were listed for OHT between January 2014 and March 2021 at our center. To minimize crossover bias, OHT recipients with a prior LVAD were excluded, and HM3 patients were censored at the time of transplant. Cohorts were propensity score-matched to reduce confounding variables. The primary outcome was 3-year survival, and the secondary outcome was mean cumulative all-cause unplanned readmission.The study population comprised 185 HM3 patients (49%) and 196 OHT patients (51%), with 104 propensity score-matched patients in each group. After propensity score matching, there was no statistical difference in 3-year survival (83.7% for HM3 vs 87.0% for OHT; P = .91; relative risk [RR], 1.00; 95% confidence interval [CI], 0.45-2.20). In the unmatched cohorts, patients age 18 to 49 years had comparable survival with HM3 and OHT (96.9% vs 95.9%; N = 91; P = 1.00; RR, 0.92; 95% CI, 0.09-9.78). Patients age 50+ years had slightly inferior survival with HM3 (75.0% vs 83.9%; N = 290; P = .60; RR, 1.51; 95% CI, 0.85-2.68). The mean number of readmissions at 3 years was higher in the HM3 group (3.89 vs 2.05; P < .001).This exploratory analysis suggests that for similar patients, HM3 may provide comparable 3-year survival to OHT as a primary treatment for heart failure but may result in more readmissions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
九门提督发布了新的文献求助10
4秒前
桂lh完成签到,获得积分20
5秒前
威武幻柏发布了新的文献求助10
6秒前
8秒前
菜菜博士发布了新的文献求助10
10秒前
xieenxe完成签到,获得积分20
11秒前
悦己完成签到,获得积分10
12秒前
黄沙漠完成签到 ,获得积分10
13秒前
13秒前
乐乐完成签到,获得积分10
13秒前
WYJ完成签到,获得积分10
15秒前
lhz发布了新的文献求助10
15秒前
上官若男应助科研通管家采纳,获得10
16秒前
完美世界应助科研通管家采纳,获得10
16秒前
wang完成签到 ,获得积分10
20秒前
鹿lu完成签到 ,获得积分10
20秒前
wcy完成签到 ,获得积分10
21秒前
nenoaowu发布了新的文献求助10
23秒前
完美世界应助菜菜博士采纳,获得10
23秒前
26秒前
粽子完成签到,获得积分10
29秒前
31秒前
大胆白凝完成签到 ,获得积分10
32秒前
Owen应助DTP采纳,获得10
35秒前
Yeung发布了新的文献求助10
36秒前
鉴定为学计算学的完成签到,获得积分10
38秒前
火山上开山完成签到 ,获得积分10
39秒前
42秒前
子车茗应助amelia采纳,获得30
42秒前
cgs完成签到,获得积分10
43秒前
yangzai完成签到 ,获得积分10
43秒前
火星上云朵完成签到 ,获得积分10
46秒前
47秒前
tutu完成签到,获得积分10
49秒前
可靠的亦竹完成签到 ,获得积分10
49秒前
韩保晨完成签到 ,获得积分10
50秒前
科研通AI2S应助cgs采纳,获得10
50秒前
果子完成签到 ,获得积分10
51秒前
潇潇雨歇完成签到,获得积分10
51秒前
星空完成签到 ,获得积分10
51秒前
高分求助中
Histotechnology: A Self-Instructional Text 5th Edition 2000
Rock-Forming Minerals, Volume 3C, Sheet Silicates: Clay Minerals 2000
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
The Healthy Socialist Life in Maoist China 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3274994
求助须知:如何正确求助?哪些是违规求助? 2914056
关于积分的说明 8371159
捐赠科研通 2584691
什么是DOI,文献DOI怎么找? 1407236
科研通“疑难数据库(出版商)”最低求助积分说明 656845
邀请新用户注册赠送积分活动 637293